Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q4 FY23 results · Jan–Mar 2023
Astec LifeSciences reported revenue from operations of ₹126.97 crore (down 53.3% from Q4 FY22) and net loss of ₹4.97 crore for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 126.97 | 271.98 | −53.3% | 117.18 | +8.4% |
| Other income | 2.57 | 6.80 | −62.2% | 3.79 | −32.0% |
| Total income | 129.55 | 278.79 | −53.5% | 120.97 | +7.1% |
| Profit before tax | (6.18) | 58.30 | Turned loss | 1.24 | Turned loss |
| Net profit for the period | (4.97) | 43.06 | Turned loss | 0.85 | Turned loss |
| Attributable to shareholders of the company | (4.98) | 43.05 | Turned loss | 0.84 | Turned loss |
| EPS, basic (₹) | (2.54) | 21.97 | Turned loss | 0.43 | Turned loss |
| Net margin (%) | -3.9 | 15.8 | 0.7 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 126.97 | 271.98 | −53.3% | 117.18 | +8.4% |
| Other income | 2.57 | 6.80 | −62.3% | 3.78 | −32.1% |
| Total income | 129.54 | 278.78 | −53.5% | 120.96 | +7.1% |
| Profit before tax | (6.21) | 58.28 | Turned loss | 1.21 | Turned loss |
| Net profit for the period | (5.00) | 43.04 | Turned loss | 0.83 | Turned loss |
| EPS, basic (₹) | (2.55) | 21.97 | Turned loss | 0.42 | Turned loss |
| Net margin (%) | -3.9 | 15.8 | 0.7 |
Consolidated
- Filed with BSE
- 04 May 2023, 11:03 IST
- Board meeting
- 02 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 04 May 2023, 11:03 IST
- Board meeting
- 02 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE